Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
- Status
- WITHDRAWN
- Phase
- PHASE2
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Diadem to Investigate the Activity and Safety of Durvalumab
- Status
- COMPLETED
- Phase
- PHASE2